Probi Logo

Probi

Develops and manufactures clinically proven probiotics for B2B supplement & nutrition partners.

PROB | ST

Overview

Corporate Details

ISIN(s):
SE0001280355
LEI:
5493004CJOCT273MU397
Country:
Sweden
Address:
Ideongatan 1A, 223 70 Lund
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Probi is an international biotechnology company that specializes in the research, development, and manufacturing of clinically documented probiotics and biotic solutions. The company operates on a B2B model, providing partners in the dietary supplement and nutrition industries with end-to-end services, from strain development to finished, private-label products. Probi's portfolio is segmented into specific health areas, including digestive, immune, metabolic, mental, and women's health, as well as solutions tailored for healthy aging and children. The firm emphasizes science-backed innovation and clinically proven efficacy for its products.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-02-03 09:20
Delisting Announcement
Avnotering av Probi
Swedish 99.1 KB
2025-02-03 09:20
Delisting Announcement
Delisting of Probi
English 103.2 KB
2025-01-22 15:55
Major Shareholding Notification
Swedish 9.1 KB
2025-01-21 09:47
Major Shareholding Notification
Swedish 8.9 KB
2025-01-20 22:01
Pre-Annual General Meeting Information
Notice of Extraordinary General Meeting in Probi AB (publ)
English 123.5 KB
2025-01-20 22:01
Pre-Annual General Meeting Information
Kallelse till extra bolagsstämma i Probi AB (publ)
Swedish 82.2 KB
2025-01-20 22:00
Delisting Announcement
Probi applies for delisting and convenes an Extraordinary General Meeting
English 109.7 KB
2025-01-20 22:00
Delisting Announcement
Probi ansöker om avnotering och kallar till extra bolagsstämma
Swedish 104.6 KB
2025-01-09 08:00
Report Publication Announcement
Probi senarelägger bokslutskommuniké för 2024
Swedish 92.1 KB
2025-01-09 08:00
Report Publication Announcement
Probi postpones year-end report 2024
English 81.1 KB
2025-01-09 08:00
Report Publication Announcement
Probi senarelägger bokslutskommuniké för 2024
Swedish 92.1 KB
2025-01-09 08:00
Report Publication Announcement
Probi postpones year-end report 2024
English 81.1 KB
2024-12-13 17:18
M&A Activity
Statement from the independent bid committee of Probi in relation to the public…
English 142.9 KB
2024-12-13 17:17
M&A Activity
Uttalande från den oberoende budkommittén i Probi med anledning av Symrise offe…
Swedish 140.4 KB
2024-11-20 07:20
M&A Activity
Probi’s Board comments on Symrise’s public takeover offer
English 101.9 KB

Automate Your Workflow. Get a real-time feed of all Probi filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Probi

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Probi via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-01-30 Jean-Yves Parisot Other Buy 142,586 49,905,100.00 SEK
2024-11-22 Jean-Yves Parisot Other Buy 42,076 14,726,600.00 SEK
2024-11-21 Jean-Yves Parisot Other Buy 77,405 27,091,750.00 SEK
2024-11-20 Jean-Yves Parisot Other Buy 169,053 59,168,550.00 SEK
2022-05-06 Henrik Lundkvist Other Buy 100 27,981.00 SEK
2022-04-29 Tom Rönnlund Other Buy 400 122,296.00 SEK
2022-04-28 Tom Rönnlund Other Buy 955 287,015.70 SEK
2020-05-06 Tom Rönnlund Other Buy 400 100,000.00 SEK

Peer Companies

Annexon, Inc. Logo
Developing C1q inhibitors for autoimmune, neurodegenerative, and ophthalmic diseases.
United States of America
ANNX
ANTEROGEN CO., LTD. Logo
Develops and commercializes adult stem cell therapies and orphan drugs for medical conditions.
South Korea
065660
Antibiotice S.A. Logo
Develops and manufactures generic medicines and APIs, specializing in anti-infectives.
Romania
ATB
Apellis Pharmaceuticals, Inc. Logo
Developing novel C3 therapies for diseases in ophthalmology, nephrology, and hematology.
United States of America
APLS
Apimeds Pharmaceuticals US, Inc. Logo
Biopharma developing non-narcotic bee venom therapies for osteoarthritis pain and inflammation.
United States of America
APUS
Apogee Therapeutics, Inc. Logo
Developing novel antibody biologics for immunological and inflammatory (I&I) diseases.
United States of America
APGE
Apollomics Inc. Logo
A clinical-stage biopharma developing targeted oncology therapies for hard-to-treat cancers.
United States of America
APLM
Apontis Pharma AG Logo
German pharma firm specializing in Single Pills for cardiovascular and chronic diseases.
Germany
APPH
Applied Therapeutics, Inc. Logo
Develops treatments for rare metabolic and central nervous system (CNS) disorders.
United States of America
APLT
Aprogen Biologics Inc. Logo
Develops and manufactures novel biologic drugs and biosimilars for the professional market.
South Korea
003060

Talk to a Data Expert

Have a question? We'll get back to you promptly.